Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. - Wikidata - awgldk - TriplyDB

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

http://www.wikidata.org/entity/Q33614365

about

HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals The HIV glycan shield as a target for broadly neutralizing antibodies The Antibody Response against HIV-1 Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 Elimination of HIV-1-infected cells by broadly neutralizing antibodies Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites Thermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120 Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Survivors Remorse: antibody-mediated protection against HIV-1.An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Induction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.

P2860

Q21090490-35EBB078-AFAB-4D27-90BC-74D9D08D2ADE Q24635002-320F0326-AFCF-4B22-909E-84653FF62BAC Q26786540-8FA8771F-E410-4136-8758-74D5917D3781 Q27000889-4387E706-10D5-4B34-9A71-535E442C83DC Q27322403-1CB309F7-0EEE-4F31-93B6-B6B0360F5A6B Q27329126-788A38B3-D46D-400D-83C1-F54AA9BC853D Q27644383-C308BD1B-76A3-4CBD-A067-66B0FB4DC90F Q27644501-49D2EC00-CB5D-4080-83F8-6945F11315AE Q27644634-F2E913D9-4CCF-4379-9B41-FD9ED5287532 Q27662167-23CA3D76-880B-4C47-845C-AD967916D0F7 Q27666407-43BA43DF-D277-47C9-A975-B26D453AA52D Q27670829-19AD24A4-4FF1-4209-812D-82348B827881 Q27674878-6B9300B6-B510-44E1-8658-924040E5B6B9 Q27675486-C89FBA24-BABF-4B0D-9861-A51349A892E2 Q27675879-FC9680A3-EDB9-4024-B214-B3D1C5B47D7F Q27677117-718E32C6-9B3F-4BF0-942A-5E5854D29C8C Q27677941-D565D740-CF5A-4EC8-95EF-A6BAA3E4357D Q27678226-F3FAF19F-675C-47C0-B257-4D3B0261D0C2 Q27678493-ECD44CA1-E031-4245-88A5-D9F205335FCB Q27679031-B6D52B55-C67E-4E0A-AA6F-89E6D11082ED Q27679559-75955E92-F9E6-41F2-AABC-EE4D7D05F67B Q27684529-5356193E-B0E6-440F-BE4F-C10E0866D044 Q27684578-A9276DC7-88BD-4024-8578-D3631773509C Q28256508-1DB97E4D-FD94-4E51-8FBA-BB17D99084F4 Q28483205-9B20E4E8-3488-4EE9-95BF-917E916FDC93 Q28484277-7BB087FA-A3A8-40B1-9E15-35332B0392C5 Q28535477-982BC59F-4FD4-4DAE-B851-FB0ADADB20B4 Q28602877-0C330EB7-AF77-48F4-8D9E-B59D07215754 Q28647225-80D20EB4-3754-4210-B521-41D03EEE3372 Q28732043-598D9EF2-67D0-44DB-880F-1AB25FC1FE22 Q28743608-2FB3D6A8-5DBF-4F7E-B085-37F19E366057 Q28752503-E3E52183-1C60-45E5-99E3-66521C0A512B Q29619511-2F22AE89-98E5-444A-B871-06D51D17DBDA Q30238730-37D74B4E-9D7B-4363-B3DD-C0B1403E3B8C Q30375785-80D14D5C-853D-40CC-A22A-B514CD1C3C95 Q30401836-1BB45263-DEAA-437C-AB4B-8A4853D45BA8 Q30524110-F09C2B03-4D0C-488F-A120-F9D1A5E589AE Q30570557-C1C93500-4D57-424B-B2B9-AA62FA7F65BC Q30578618-AF3D8674-258C-42FE-B726-F095D0A6FADB Q30603475-1C70033E-61B1-4934-BBC0-74148CAC3DB9

P2860

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

http://www.wikidata.org/entity/Q33614365

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Tiered categorization of a div ...... nt of neutralizing antibodies.

@ast

Tiered categorization of a div ...... nt of neutralizing antibodies.

@en

type

label

Tiered categorization of a div ...... nt of neutralizing antibodies.

@ast

Tiered categorization of a div ...... nt of neutralizing antibodies.

@en

prefLabel

Tiered categorization of a div ...... nt of neutralizing antibodies.

@ast

Tiered categorization of a div ...... nt of neutralizing antibodies.

@en

P1433

Q33614365-95FEE4E4-D4EB-415E-8427-A3A496905476

P1476

Q33614365-EF926F21-2A01-4871-AE2A-50BAEBCA6B82

P2093

Q33614365-074A1DD8-B416-4410-9621-8CE5157B847E

Q33614365-197E6B62-D30D-4548-87E1-51133B4073CA

Q33614365-363171D9-8E4A-4388-A358-44E9EB89B3B3

Q33614365-6D0B6348-0B03-45FE-A80B-1161A14FE03F

Q33614365-7CC1DC1D-ED42-43E0-974B-E6A30B61DE4E

Q33614365-87F7F022-DD59-4417-9125-05784C386D72

Q33614365-88B3869C-48C4-4686-BC28-6BBD089C5CAF

Q33614365-A542110A-11C4-4CB8-A2AF-9EE2624E7C70

Q33614365-B5423ED1-8D14-4CCA-87D3-71ADC8E3D774

Q33614365-CACE35C2-E8F2-45CA-AA60-4D8169CBA02C

P2860

Q33614365-0773C1E6-2CDD-491D-841B-30C9F1E5EE71

Q33614365-0BBA2522-9B18-4309-85D6-1974236B633F

Q33614365-10CA0975-079F-4608-AD09-02A2360B7276

Q33614365-1263EDB7-2A36-467A-967E-F74DDD7ACCAF

Q33614365-16EF511D-64DC-47AB-A87C-FA9662FC635F

Q33614365-17CB414F-79BD-4D09-AE84-681B35A74B78

Q33614365-1F988B3C-D8E6-4F0C-BFA4-A38E9416E304

Q33614365-2ACDCA0E-257B-4660-9316-C4BB2DDD70CF

Q33614365-2AF252E3-00F6-43E0-835F-110ACA7C9781

Q33614365-2B178393-A933-41B9-8426-C4500CD1127B

P304

Q33614365-FBE83013-E93B-4A2C-A835-13C191F3438F

P31

Q33614365-B592EB21-AAC9-4BBB-9802-9CA40ABC8682

P356

Q33614365-51DA3E3C-C65F-4310-81E6-7BC721280190

P433

Q33614365-52D2CD8B-917A-4864-8739-F1C03A07EB5A

P478

Q33614365-1D2FE635-99A6-41ED-A752-AEAF029558DD

P50

Q33614365-379BFBE4-E542-434A-A93B-331A33E87A17

Q33614365-382058BB-64D1-4671-9993-175C0A5E9A06

Q33614365-69289B5A-F5C2-41CF-B782-0AB351C6CD1A

Q33614365-7C3AE301-2629-47F1-8FC4-A2EAB859421C

Q33614365-A83DAF5C-0847-4497-8340-3362F79DE5A1

Q33614365-C2E2974D-D019-4EDE-865B-951694BFD137

Q33614365-C4B1C72E-E34C-4A34-B792-120FEC69B57A

P577

Q33614365-4245A5F9-1D7B-471E-82A8-D96D44CCACB8

P698

Q33614365-C897502A-689F-43EE-A5BD-3E86A8FB41B3

P921

Q33614365-72105EEE-20B0-46E9-9A71-5E391E16C6F8

P932

Q33614365-F3FCB3F5-94F9-43A1-ACB0-B623B6530213

P356

P1433

Journal of Virology

P1476

Tiered categorization of a div ...... nt of neutralizing antibodies.

@en

P2093

Alan Lapedes

http://www.w3.org/2001/XMLSchema#string

Ayush Giri

http://www.w3.org/2001/XMLSchema#string

Blake Wood

http://www.w3.org/2001/XMLSchema#string

Colleen Devoy

http://www.w3.org/2001/XMLSchema#string

Lauren E Grandpre

http://www.w3.org/2001/XMLSchema#string

Linda Harris

http://www.w3.org/2001/XMLSchema#string

Marcus G Daniels

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

Natalie Hawkins

http://www.w3.org/2001/XMLSchema#string

Peter B Gilbert

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

GP120: target for neutralizing HIV-1 antibodies

Antibody neutralization and escape by HIV-1

Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

P304

1439-1452

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02108-09

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Tanmoy Bhattacharya

David C Montefiori

Francine E McCutchan

Victoria R Polonis

P577

2009-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19939925

http://www.w3.org/2001/XMLSchema#string

P921

P932

2812321

http://www.w3.org/2001/XMLSchema#string